Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel

Zhijie Wang, Jianchun Duan, Shangli Cai, +27

JAMA Oncology

A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma

Wu‐tong Ju, Ronghui Xia, Dongwang Zhu, +17

Nature Communications

Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial

Wenwen Zhang, Shuang Tong, Bingyang Hu, +22

Journal for ImmunoTherapy of Cancer

Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients

Dongsheng Yue, Weiran Liu, Chen Chen, +13

Translational Lung Cancer Research

Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer

Yuezong Bai, Tong Xie, Zhenghang Wang, +7

Journal for ImmunoTherapy of Cancer

Allele Frequency–Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors

Zhijie Wang, Jianchun Duan, Guoqiang Wang, +30

Journal of Thoracic Oncology

Overall SurvivalMedicinePathologyImmune Checkpoint InhibitorNsclc Treated +4

A Novel Ten-Gene Signature Predicting Prognosis in Hepatocellular Carcinoma

Taicheng Zhou, Zhihua Cai, Ning Ma, +6

Frontiers in Cell and Developmental Biology

Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR/MSI-H gastric adenocarcinoma

Zhenghang Wang, Xinyu Wang, Yu Xu, +14

BMC Medicine

A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer

Jian Xiao, Wenyun Li, Yan Huang, +11

BMC Cancer

Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer

Xiaofei Zhang, Tiebo Mao, Bei Zhang, +26

EBioMedicine